Abstract
Corticotropin-releasing factor (CRF) is a 41-amino acid neuropeptide that is involved in stress-related physiology and behavior, including control of the hypothalamic-pituitary-adrenal (HPA) axis. Members of the CRF family of neuropeptides, including urocortin 1 (UCN 1), UCN 2, and UCN 3, bind to the G protein-coupled receptors, CRF type 1 (CRF1) and CRF2 receptors. In addition, CRF binding protein (CRFBP) binds both CRF and UCN 1 and can modulate their activities. There are multiple mechanisms through which CRF-related peptides may influence emotional behavior, one of which is through altering the activity of brainstem neuromodulatory systems, including serotonergic systems. CRF and CRF-related peptides act within the dorsal raphe nucleus (DR), the major source for serotonin (5-HT) in the brain, to alter the neuronal activity of specific subsets of serotonergic neurons and to influence stress-related behavior. CRF-containing axonal fibers innervate the DR in a topographically organized manner, which may contribute to the ability of CRF to alter the activity of specific subsets of serotonergic neurons. CRF and CRF-related peptides can either increase or decrease serotonergic neuronal firing rates and serotonin release, depending on their concentrations and on the specific CRF receptor subtype(s) involved. This review aims to describe the interactions between CRF-related peptides and serotonergic systems, the consequences for stress-related behavior, and implications for vulnerability to anxiety and affective disorders.
Introduction
Corticotropin-releasing factor (CRF) is a 41-amino acid neuropeptide that is involved in stress-related physiology and behavior, including control of the hypothalamic-pituitary-adrenal (HPA) axis (Vale et al., , ). CRF has been implicated in the etiology and pathophysiology of stress-related disorders such as anxiety and affective disorders (Dunn and Berridge, ; Binder and Nemeroff, ). One of the ways in which CRF may play a role in the etiology and pathophysiology of anxiety and affective disorders is through modulation of brainstem neuromodulatory systems such as serotonergic systems. Serotonin (5-hydroxytryptamine; 5-HT) has long been implicated in control of emotional behavior as well as anxiety and affective disorders (Ressler and Nemeroff, ). Consequently, understanding the interactions between CRF, CRF-related neuropeptides, and serotonergic systems is likely to lead to advances in understanding the biological basis of anxiety and affective disorders. This review aims to describe the interactions among CRF, CRF-related neuropeptides, and serotonergic systems and the importance of these interactions in modulating emotional behaviors involved in anxiety and affective disorders.
CRF family of peptides
The CRF family of neuropeptides includes CRF as well as the urocortins (UCN), UCN 1, UCN 2, and UCN 3, structurally related peptides that have been discovered more recently (Vaughan et al., ; Donaldson et al., ; Zhao et al., ; Lewis et al., ; Reyes et al., ; Lovejoy and Jahan, ; Fekete and Zorrilla, ). UCN 1 is a 40-amino acid peptide while both UCN 2 and 3 are 38-amino acid peptides. The UCN's, like CRF, have been implicated in stress-related physiology and behavior, including modulation of the HPA axis (Vaughan et al., ; Reul and Holsboer, ). There are two receptors that CRF and the UCN's bind to with high affinity, which are designated as CRF1 (Perrin et al., ) and CRF2 receptors (Lovenberg et al., ). They are both G protein-coupled receptors belonging to the B1 sub-family of G-coupled receptors and couple to both Gs and Gq (Perrin et al., ) with varying affinities for the neuropeptides in the CRF family. CRF itself has a greater affinity for CRF1 receptors while UCN 1 binds with high affinity to both receptors and UCN 2 and UCN 3 both preferentially bind to CRF2 receptors (Vaughan et al., ; Lewis et al., ; Reyes et al., ). Several splice variants for both receptor subtypes have also been reported and the structural and functional properties of these splice variants have been reviewed previously (Dautzenberg et al., ). Finally, the CRF binding protein (CRFBP) shows high affinity for both CRF and UCN 1 but has little affinity for UCN 2 or 3 (Lewis et al., ).
Distribution of CRF containing neurons in neural circuits controlling emotional behavior
Corticotropin-releasing factor-containing neurons are widely distributed throughout both the rat and mouse brains, with several areas differing in expression levels, based on patterns of immunohistochemical staining in the two species (Wang et al., ). Given the wide distribution of CRF-containing neurons within the central nervous system, the idea that CRF works as a neuromodulator has received considerable attention in the past few decades. The main focus of this review is the role of CRF and CRF-related neuropeptides in stress-related emotional behavior, and therefore we focus on the distribution of these neuropeptides in neural circuits implicated in control of stress-related emotional behavior. A full consideration of the distribution of CRF and CRF-related neuropeptides can be found in previous reviews focusing on the chemical neuroanatomy (Swanson et al., ; Sakanaka et al., ; Kozicz, ).
A major source for CRF in the brain is the paraventricular nucleus of the hypothalamus (PVN) (Sakanaka et al., ). CRF synthesized in the PVN, via projections to the median eminence, plays a primary role in control of the HPA axis. However, several extrahypothalamic brain regions involved in control of emotional behavior have CRF-containing neurons. In particular, both the central nucleus of the amygdala (CE) and the bed nucleus of the stria terminalis (BNST) contain CRF-immunoreactive neurons with extensive projections to brainstem structures controlling emotional behavior (Gray, ; Wang et al., ). Other regions with CRF expressing neurons that are involved in control of emotional behavior include the hippocampus, subiculum, lateral septum, and periaqueductal gray (Sakanaka et al., ; Calandreau et al., ). The localization of CRF in brain regions involved in control of emotional behavior implicated CRF as an important neuromodulator, in addition to an important neurohormonal function (Gray, ).
Distribution of UCN 1, 2, and 3 containing neurons
The UCN's are expressed in discrete regions within the brain. The non-preganglionic Edinger-Westphal nucleus has a large number of UCN 1 neurons (Kozicz et al., ). Additionally, the lateral superior olivary and supraoptic nuclei also have been shown to have mRNA and immunoreactivity for UCN 1 (Bittencourt et al., ; Lewis et al., ). UCN 2 is mainly localized in subcortical structures including the locus coeruleus (Reyes et al., ). UCN 3 is also localized to discrete areas of the brain including an area encircling the columns of the fornix in the rostral hypothalamus, the posterior portion of the BNST and an area dorsolateral to the caudal portion of the dorsomedial hypothalamic nucleus (Kuperman et al., ). Another grouping of UCN 3 neurons is located in the anterodorsal part of the medial amygdaloid nucleus (Lewis et al., ; Li et al., ).
Distribution of CRF receptors in emotion-related brain regions
The distribution of CRF1 and CRF2 receptors within rodent brain has been well-described with CRF1 receptors being more widely distributed while CRF2 receptors are more restricted to subcortical areas (Potter et al., ; Chalmers et al., ; Van Pett et al., ). The hippocampus contains both CRF receptors as does the periaqueductal gray (Van Pett et al., ). The amygdala expresses both receptor subtypes with low levels of only CRF 1 receptors in the CE (Van Pett et al., ). All portions of the BNST have been shown to have CRF1 receptors while the posterior portion of the BNST also has CRF2 receptors (Van Pett et al., ). Importantly for this review, the raphe nuclei including the DR and median raphe nucleus (MnR) both have CRF1 and CRF2 receptors with the DR having higher levels of CRF2 and the MnR having about equal amounts of both receptors (Van Pett et al., ; Day et al., ).
The functional subsets of 5-HT neurons based on functional neuroanatomy and afferent and efferent connections
In order to discuss the possibility that CRF and CRF-related peptides control functional subsets of serotonergic neurons involved in control of emotional behavior, it is first useful to consider the evidence for a topographical and functional organization of the midbrain raphe complex. The midbrain raphe complex includes serotonergic systems located within the DR, the median raphe nucleus, caudal linear nucleus, pontomesencephalic reticular formation, supralemniscal cell group, and interpeduncular nucleus (Hale et al., ) Here we will focus on the organization of the DR. The DR is topographically organized and can be divided into subregions making up the rostral, dorsal, ventral, ventrolateral, interfascicular, and caudal portions. It is beyond the scope of this review to describe in detail the topography but we will, in brief, describe the major subdivisions here and refer the reader to previous reviews for a thorough review of the DR serotonergic system and its topography (Lowry, ; Lowry et al., , ; Hale and Lowry, ; Hale et al., ).
The rostral DR
The rostral portion of the DR, which is located from approximately −7.04 to −7.30 mm from bregma in the rat brain (Paxinos and Watson, ), receives projections from cingulate, orbital and infralimbic cortices, as well as a small number of projections from the CE, BNST, and substantia inominata and larger numbers from the paraventricular and other hypothalamic nuclei (Peyron et al., ). In turn, the rostral DR projects to the caudate putamen with collaterals to the substantia nigra, and also projects to the subthalamic nucleus and substantia inominata (Steinbusch, ; Imai et al., ; Canteras et al., ; Grove, ). Data show that 6 weeks of voluntary wheel running increases 5-HT1A receptor mRNA in the rostral and mid-rostrocaudal DR as well as decreases 5-HT1B receptor and 5-HT transporter mRNA (Greenwood et al., , ). Voluntary wheel running is also associated with a protective effect against the behavioral deficits associated with uncontrollable tail shock such as exaggerated freezing in a shuttle box (Greenwood et al., , ). These data show that the rostral DR is connected with emotion-related brain regions and that altered emotional behavior is associated with serotonergic changes in this brain region.
The dorsal part of the DR
The DRD is located from approximately −7.30 to −8.30 mm from bregma in the rat brain (Paxinos and Watson, ). The DRD receives projections from areas associated with the control of emotional behaviors including the lateral and ventral orbitofrontal and infralimbic cortices, CE, BNST, and the dorsal, dorsomedial, lateral, and posterior hypothalamic nuclei (Peyron et al., ). Further, the DRD projects to areas associated with control of emotional behaviors including the CE, BLA, BNST, nucleus accumbens (Acb), medial prefrontal cortex (mPFC), and dorsal hypothalamus (Van Bockstaele et al., ; Commons et al., ; Hale et al., ). In addition, the DRD sends a number of collateral projections to functionally related forebrain targets involved in emotional behavior. Anxiety related stimuli such as multiple classes of anxiogenic drugs including UCN 2, or anxiety producing situations including exposure to an open-field test arena, or social defeat, lead to increased activation of DRD serotonergic neurons as measured by c-Fos immunoreactivity (Abrams et al., ; Gardner et al., ; Bouwknecht et al., ; Hale et al., , ; Paul et al., ). Lastly, chronic corticosterone in the drinking water, which increases anxiety-like behavior in a social interaction task, open field task, and elevated plus maze, increases tryptophan hydroxylase 2 (TPH) mRNA in the DRD (Donner et al., ). The DRD is connected with emotion-related brain regions including the BNST (see Figure 1) and activation by anxiogenic stimuli show that it may be an important region involved in the control of emotion-related behavioral output.
Figure 1
The ventral part of the DR
The DRV is located from approximately −7.30 to −8.30 mm from bregma in the rat brain (Paxinos and Watson, ). The DRV receives projections from the cingulate and lateral orbital cortices, CE, and dorsomedial hypothalamic nucleus, with less dense projections from other amygdaloid nuclei and cortex (Peyron et al., ). The DRV in turn projects to sensorimotor, ventrolateral orbital, frontal, motor, and visual cortices and the caudate putamen (Steinbusch et al., ; Steinbusch, ; Waterhouse et al., ; Kazakov et al., ). Because of the projections to frontal, visual, and motor cortex, it is likely that this region of the DR is involved in directed behaviors that may or may not have an emotional content. Further research of DRV serotonergic neurons is needed for a better understanding of their functional properties.
The ventrolateral part of the DR and ventrolateral periaqueductal gray
The DRVL/VLPAG is located lateral to the DRD and occurs approximately from −7.64 to −8.54 mm from bregma in the rat brain (Paxinos and Watson, ). The DRVL/VLPAG receives projections from a number of brain regions involved in autonomic and emotional control. These include projections from the amygdala, with heavy innervation by the CE and moderate innervation by the dorsolateral medial amygdala with additional projections from the ventromedial prefrontal cortex, hypothalamus, and the retina (Hurley et al., ; Shen and Semba, ; Lee et al., , ). The DRVL/VLPAG gives rise to projections involved in visual function including the superior colliculus and lateral geniculate nucleus (O'Hearn and Molliver, ; Waterhouse et al., ). Further, the DRVL/VLPAG also projects to the hypothalamus, medulla, PAG, and subcortical somatosensory regions, and data also suggest that DRVL/VLPAG serotonergic neurons control, via multisynaptic connections, presympathomotor neurons in the spinal cord (Beitz, ; Stezhka and Lovick, ; Ljubic-Thibal et al., ; Underwood et al., ; Kirifides et al., ; Bago et al., ; Kerman et al., ). The DRVL/VLPAG connections suggest that this region is important in control over panic-like and fight-or-flight behaviors. Consistent with this hypothesis, data show that panic-inducing stimuli such as hypercapnia or sodium lactate activate DRVL/VLPAG serotonergic neurons, but not in rats that are made panic prone, suggesting that the DRVL/VLPAG may inhibit panic in normal rats (Johnson et al., , ).
Recent data suggest that the DRVL/VLPAG may be an important component in the interdependence of fear- and panic-like responses. Data show that when a rat is fear conditioned and experiencing CE-mediated fear it is less likely to exhibit panic-like behaviors when given dorsal PAG electrical stimulation (Magierek et al., ). Clinical evidence supporting the hypothesis that fear may inhibit panic-like responses comes from a recent study in which 3 people with selective lesions of the amygdala were unable to experience normal fear but experienced panic when given CO2 inhalation (Feinstein et al., ). We propose that the CE, when activated, may serve to selectively inhibit panic through connections with DRVL/VLPAG serotonergic neurons (see Figure 2 for the proposed circuit). People with bilateral amygdala lesions are unable to inhibit CO2-induced panic responses while healthy controls generally do not experience panic when given CO2 (Goetz et al., ). The data thus suggest an important role of serotonergic neurons in the DRVL/VLPAG for control of emotional behaviors including fear and panic.
Figure 2
The caudal portion of the DR
That most caudal subdivision of the DR (DRC) is located from approximately −8.30 to −9.30 mm bregma in the rat brain (Paxinos and Watson, ). The DRC receives a number of projections including from the mPFC, the preoptic area, arcuate nucleus, and perifornical and lateral hypothalamic areas, lateral habenula, and substantia nigra with more sparse afferents from both the CE and BNST (Lee et al., ). In turn, the DRC projects to brain regions involved in control of emotional behavior including the LC, amygdala, paraventricular nucleus of the thalamus and ventral hippocampus (Imai et al., ; Krout et al., ). Furthermore, the DRC has been shown to be involved in the behavioral deficits seen with inescapable stress and is activated following social defeat, administration of anxiogenic drugs, and administration of ligands including CRF and UCN 2 suggesting it, along with other regions of the DR, plays in an important role in the control of emotional behavior (Hammack et al., , ; Abrams et al., ; Gardner et al., ).
The interfascicular part of the DR
The interfascicular part of the DR (DRI) is located approximately between −8.18 and −8.80 mm from bregma in the rat brain (Paxinos and Watson, ). Although not well-researched, studies have shown projections from the LC, median preoptic area, and the lateral parabrachial nucleus to the DRI (Saper and Loewy, ; Holstege, ; Lee et al., ; Kim et al., ). The DRI has, however, been shown to project to a number of regions. The DRI has projections to both dorsal and ventral hippocampus, medial septum, entorhinal, dorsolateral prefrontal, medial orbital, and anterior cingulate cortex and mediodorsal thalamus (Azmitia and Segal, ; Kohler and Steinbusch, ; Kohler et al., ; Porrino and Goldman-Rakic, ; Krout et al., ). The DRI, along with the DRVL/VLPAG, has been shown to be activated by a number of peripheral sensory stimuli, including peripheral injection of heat-killed Mycobacterium vaccae or lipopolysaccharide (LPS), and exposure to warm and cold temperature (Hollis et al., ; Hale et al., ; Kelly et al., ). Activation of DRI serotonergic neurons is associated with antidepressant-like behavioral responses (Lowry et al., ). This then suggests, consistent with its pattern of efferents that this area of the DR may also be important in controlling certain emotional behaviors.
Distribution of 5-HT receptors in emotion related brain regions
There are at least 14 different 5-HT receptors that have been identified, all of which have been thoroughly reviewed previously (Hoyer et al., , ; Barnes and Sharp, ; Smythies, ; Hannon and Hoyer, ). The receptors are divided into 7 families (1–7), and all, except the 5-HT3 receptors, are G protein-coupled metabotrobic receptors whereas the 5-HT3 receptor is a ligand-gated ion channel (Barnes and Sharp, ). Specifically, the 5-HT1 and 5-HT5 receptors are Gi/o coupled, 5-HT2 receptors are Gq/11 coupled, and lastly, 5-HT4, 5-HT6, and 5-HT7 receptors are Gs coupled (Hannon and Hoyer, ). As well, 5-HT receptors are located both pre and post-synaptically, can be inhibitory or excitatory, and can be located on both γ-aminobutyric acid (GABA)ergic and glutamatergic neurons leading to a highly intricate and complex system within the brain (Rainnie, ; Guo and Rainnie, ).
Serotonin receptors are located in the amygdala and the BNST, which are thought to be important regions for fear and anxiety-behaviors. In addition, serotonin receptors have been implicated in playing a role in emotion-related behaviors in the hippocampus and the mPFC. Although all 5-HT receptors have been identified within the amygdala, particular attention has been paid to the 5-HT1A and 5-HT2C receptors (Park and Williams, ; Asan et al., ). Specifically, the 5-HT1A receptors in the CE have been shown to be involved in the reduction of anxiety-like behaviors while 5-HT2C receptors are associated with an increase in anxiety-like behaviors (Li et al., ). The hippocampus plays an important role in conditioned fear and 5-HT receptors appear to play an integral role (Eriksson et al., ). In the hippocampus, 5-HT1A receptor activation appears to inhibit emotion-related behavior associated with fear conditioning (Stiedl et al., ). However, 5-HT7 receptor activation appears to enhance emotion-related behavior, especially when the 5-HT1A receptors are blocked (Eriksson et al., ), while a lack of 5-HT7 receptors impairs fear learning (Roberts et al., ). Further, evidence suggests a role for activating 5-HT2A/C receptors in the hippocampus in increasing GABA release (Shen and Andrade, ) while hippocampal 5-HT2C activation has been associated with an increase in anxiety-like behaviors (Alves et al., ). Additionally, 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C, and 5-HT7 receptors have been implicated in playing a role in emotional behaviors in the BNST, with the 5-HT1 receptor activation linked to reduced anxiety and the others linked to increased anxiety (Levita et al., ; Guo et al., ; Hammack et al., ; Guo and Rainnie, ). Lastly, the mPFC has been shown to be an important area involved in emotion-related behaviors and partially controlled by 5-HT (Amat et al., ). While 5-HT2C receptors are located in this region, they have yet to be implicated in emotion-related behaviors outside of drug seeking (Pentkowski et al., ). However, 5-HT1A receptors in the mPFC appear to play an important role in regulating 5-HT release from the DR such that stressful environments produce an increase in 5-HT release, which in turn appears to enact a negative feedback loop that turns off 5-HT release in the mPFC through glutamatergic and GABAergic neurons (Altieri et al., ). While both inhibitory and excitatory receptors are located in these brain regions, it is likely they work in concert depending on the context of the environment. For example, anxiety and fear are restrained unless the situation dictates the appropriateness of these emotions or in terms of psychopathology, these systems are no longer in concert to restrain anxiety and fear in inappropriate situations (Hammack et al., ).
Distribution of CRF and CRF receptors within the dorsal raphe nucleus
As discussed briefly above, one mechanism through which CRF and the UCN's can influence emotional behavior is through actions on brainstem neuromodulatory systems such as serotonergic systems. The DR, along with the MnR, is the major source for 5-HT in the brain (Steinbusch, ). Although the DR is a main source for 5-HT, it also contains neurons that express other neurotransmitters and neuropeptides, including CRF. Corticotropin-releasing factor-immunoreactive neurons have been observed in the DR in colchicine-treated rats (Commons et al., ). Corticotropin-releasing factor-positive neurons were predominately found in the dorsomedial subregion of the mid-rostrocaudal DRD with smaller numbers of positive cells in the ventrolateral part of the DRVL/VLPAG. Importantly, these CRF-immunoreative cells were mostly dual labeled for TPH indicating that these were also serotonergic neurons. In addition, CRF-positive cells were largely absent from the ventromedial and most caudal portions of the DRD and DRVL/VLPAG while CRF-positive fibers were seen to traverse the lateral edge of the rostral DRV. It was also demonstrated through anterograde tracing that the dorsomedial neurons had dense projections to the CE, a region involved in the control of emotion such as fear and anxiety (Gray, ; Davis, ; Commons et al., ; Phelps and LeDoux, ). Moreover, CRF application in the mid-rostrocaudal DRD increases 5-HT in the CE and freezing behaviors (Forster et al., ). Because the CE is involved in emotion and has direct CRF connections with specific regions of the DR, it is situated to control serotonergic systems and modulate emotion-related behavioral output.
The dorsomedial neurons of the mid-rostrocaudal DR have dense CRF projections to the BNST while the BNST also has reciprocal connections with the DRD and DRC (Van Bockstaele et al., ; Petit et al., ; Peyron et al., ; Dong et al., ; Commons et al., ; Dong and Swanson, ). The BNST has been shown to be an important region controlling emotional behaviors such as alterations in acoustic startle behavior (Davis et al., ). CRF innervation of the DRD/DRC by BNST CRF positive neurons has not been directly shown, however, control of emotional-like behavior by CRF projections from the BNST to the caudal DRD has been suggested as BNST lesions block escape deficiencies produced after inescapable shock while administration of CRF into the DRC mimics the effects of inescapable shock on inhibiting escape behaviors (Hammack et al., , ). Moreover, overexpression (OE) of CRF in the BNST induces a decrease in CRF2 receptor mRNA specifically within the DRD suggesting that the BNST has direct CRF projections to this brain region (Sink et al., ). Given the role of the BNST in control of emotional behaviors and its potential connections with subregions of the DR, it is an important structure that most likely contributes to control of emotional behavioral output through CRF-5-HT interactions.
The distribution of CRF receptors within the DR is also topographically organized and both CRF1 and CRF2 receptors are colocalized with serotonergic neurons as well as non-serotonergic neurons (Day et al., ; Waselus et al., ). CRF1 receptor mRNA density is considerably lower than CRF2 receptor mRNA in the DR (Van Pett et al., ). CRF1 receptors, using immunohistochemistry and electron microscopy, are present on the plasma membrane of dendrites in the DR as well as within the cytoplasm in roughly equal distribution (Waselus et al., ). CRF1 receptors are located in the dorsal portion of the DRVL/VLPAG and have been shown to be colocalized there with GABA in 36% of neurons triple labeled for c-Fos, GABA, and CRF1 receptors after forced swim stress (Roche et al., ; Day et al., ). These data suggest that CRF receptor activation can serve to modulate serotonergic activity both directly and indirectly.
CRF2 receptors are topographically organized in the DR and are expressed in both serotonergic and non-serotonergic neurons. CRF2 receptors have been demonstrated using immunohistochemistry and electron microscopy in the DR on both axon terminals and in dendrites with a predominant level within the cytoplasm (Waselus et al., ). The CRF2 receptor is apparent in low numbers in the rostral portion of the DR but increases in greater number in more caudal sections of the DR as shown with in situ hybridization histochemistry and immunoreactivity (Day et al., ; Lukkes et al., ). In addition, the effects of CRF administration in the caudal portions of the DR is only blocked by CRF2 but not CRF1 receptor antagonists (Hammack et al., , ; Staub et al., , ). Further, CRF2 receptors also show a topographically organized colocalization with 5-HT neurons and GABA neurons in the DR (Day et al., ). Specifically, CRF2 receptor mRNA in the rostral and mid-rostrocaudal levels of the DR is almost exclusively colocalized with 5-HT neurons while in more caudal regions, about half of the CRF2 receptor mRNA is colocalized in GABAergic neurons (Day et al., ).
CRF and UCN 1 fibers are topographically organized in the DR but much less is known about UCN 2 and UCN 3 fibers. Corticotropin-releasing factor-containing axons are more dense in the medial ventral portion of the rostral DR and then more dense in the dorsolateral DR in more caudal regions with less density in the medial ventral portion (Valentino et al., ). This topographical organization suggests that CRF is able to modulate 5-HT in a complex and dynamic manner to influence emotional behavior given that 5-HT neurons are also topographically organized (Hale and Lowry, ; Hale et al., ). UCN 1 fibers have also been described in the DR including within DRD, DRV, and DRVL subregions suggesting the possibility that UCN 1 also influences serotonergic systems and emotional behavior through CRF2 (Vaughan et al., ). The physiological involvement of UCN 2 and 3 in the modulation of the DR and 5-HT is little known as the DR shows very sparse or no innervation by either UCN 2 or 3 (Reyes et al., ; Li et al., ). Nevertheless, selective activation of CRF2 receptors in the DR does modulate and mediate emotional behaviors (described below), suggesting that further work looking into the role of the UCN's in the DR is necessary to elucidate their physiological role.
Mechanisms of CRF/5-HT interactions
CRF and UCNs effects on DR neuronal firing
CRF has been shown to alter DR neuronal firing rates in vivo and in vitro. Studies looking at the response of DR neurons in vivo have shown a bimodal response to CRF within the medial rostral portion of the DR in that low doses given either intracerebroventricularly (i.c.v) or directly into the DR inhibit neuronal firing while higher doses increase firing (Kirby et al., ; Price et al., ) consistent with other data that show a similar pattern of effects on 5-HT release in the lateral striatum and the lateral septum (Price et al., ; Price and Lucki, ). The response of 5-HT neurons in the DR to CRF has been shown to be topographically organized in vitro with more serotonergic neurons responding in the ventral portion of the DR compared to the dorsomedial aspect of the DR (Lowry et al., ). Although the majority of neurons in this region respond with an increase in firing rates, many were non-responsive and several showed a decreased firing rate. Stress has been shown to alter the response of serotonergic neuron firing rates after CRF application in that more neurons respond with increased firing rates and have a greater rate of firing compared to control animals, suggesting that CRF plays an important role after stress to modulate the serotonergic system (Lowry et al., ). Further studies have shown that CRF2 receptors move from being predominately within the cytoplasm and then move to the plasma membrane after stress (Waselus et al., ) although the mechanism for increased responsiveness and increased firing rates in serotonergic cells to CRF after stress is not known. These data thus show that the interaction between CRF and 5-HT on neuronal activity is modulated by the region of the DR, the amount of CRF released, and prior experience.
Further substantiating the evidence that the members of the CRF family of peptides can have multiple influences on 5-HT, CRF2 receptors seem to play a dual role in the DR on neuronal firing while CRF1 receptor activation seems to be inhibitory (Kirby et al., ). Small amounts (0.1 − 10 ng) of UCN 2 injected into the mid-rostrocaudal DR inhibit neuronal firing in 5-HT neurons whereas higher amounts (30 ng) of UCN 2 increase firing in 5-HT neurons and this effect is blocked by selective CRF2 receptor antagonists (Pernar et al., ). Furthermore, this high dose of UCN 2 also inhibited more non-5-HT neurons than the low dose which could indicate inhibition of GABA neurons through CRF2 receptors, which would disinhibit 5-HT neurons and result in increased serotonergic firing. CRF1 receptors also appear to be involved in the inhibition of neuronal firing after CRF administration in the DR as this effect can be blocked with a specific CRF1 receptor antagonist (Kirby et al., ).
CRF and UCNs effects on serotonergic neurons as measured by c-Fos
The members of the CRF family of neuropeptides induce topographically organized neuronal activation as measured by c-Fos. CRF, when infused i.c.v., produces a topographically organized neuronal activation within the DR in medial prefrontal cortex-projecting neurons with a higher percent of activation in caudal portions of the DR as measured by c-Fos (Meloni et al., ). Specifically, i.c.v. infusion of CRF (1 μg), induces c-Fos positive neurons in the entire DR, with higher numbers of positive cells seen in more caudal regions compared to more rostral regions (Meloni et al., ). UCN 1 (1–10 μg) given i.c.v. has also been shown to increase c-Fos in the DR although topographical activation has not been described (Bittencourt and Sawchenko, ). Additional studies show topographically organized activation of serotonergic and non-serotonergic DR neurons by i.c.v. infusion of 2 μg of UCN 2 (Staub et al., , ; Hale et al., ). Specifically, c-Fos was seen in the mid-rostrocaudal DRD and the DRC and this activation was blocked by a specific CRF2 receptor antagonist. Consistent with these data, direct infusion of UCN 2 (100 ng) into the DR also produces increased c-Fos within the DR but the effect is more widespread throughout the DR and again this is blocked using a specific CRF2 receptor antagonist (Amat et al., ). Moreover, UCN 2 activation of DR neurons includes activation of ventricle/periventricular-projecting serotonergic neurons as well as non-ventricle/periventricular-projecting serotonergic neurons, suggesting that CRF2 ligands could play an important physiological role in behavioral consequences of CRF2 receptor activation although further examination is needed (Amat et al., ; Hale et al., ). Taken together, these data show that both CRF1 and CRF2 receptor agonists activate DR neurons in a topographically organized fashion such that the mid-rostrocaudal and caudal portions of the DR appear to be preferentially activated, suggesting that these regions are important in CRF-5HT interactions.
CRF receptor activation alters serotonergic neurotransmission as measured by microdialysis
CRF receptor activation following i.c.v. administration of CRF or CRF-related neuropeptides induces changes in extracellular 5-HT concentrations in specific brain regions involved in control of emotional behavior, including the hippocampus, as measured by microdialysis (Linthorst et al., ; Kagamiishi et al., ; De Groote et al., ). However, chronic i.c.v. CRF infusion (1 μg/1 μL/h for 7 days) produces no basal difference in 5-HT levels in the hippocampus but does blunt the elevation in 5-HT after LPS injection, suggesting chronic elevation of CRF blunts stress-induced release of 5-HT in projection regions of the DR (Linthorst et al., ). While CRF receptor activation following i.c.v. administration of CRF or CRF-related neuropeptides can increase 5-HT release, it can also decrease release. I.c.v. CRF produces a decrease in 5-HT release in both the lateral septum and lateral striatum at a low dose (0.3 μg) while this manipulation either does not change 5-HT concentrations or increases concentrations at a higher dose (3.0 μg) (Price et al., , ; Price and Lucki, ). Both 5-HT1A and 2A receptor activation in the lateral septum has been associated with increased anxiety-like behavior, which would correspond with increased release of 5-HT in this region (Cheeta et al., ; de Paula et al., ). The decrease in 5-HT release in the lateral septum may allow for more proactive behaviors such as exploration to occur when placed in a mildly stressful situation (low dose of CRF) while a very stressful (high CRF dose) situation could induce more reactive behaviors like freezing. Because CRF receptors are located in other regions besides the DR, these effects of i.c.v CRF receptor agonists likely result from activating circuits that are connected with the DR as well as directly activating receptors within the DR.
Intra-DR CRF receptor activation induces changes in 5-HT concentrations in specific emotion-related brain regions, similar to effects seen with i.c.v. administration of CRF receptor agonists. CRF (0.5 μg) injected into the medial portion of the DR, including both the dorsal and ventral aspects, increases 5-HT release in the prefrontal cortex after a 60 min delay (Forster et al., ). Activation of the DR by 0.5 μg CRF injection also produces an immediate increase in 5-HT in the CE (Forster et al., ; Lukkes et al., ; Scholl et al., ). Further, CRF2 receptor activation in the caudal DR produces an increase in 5-HT in the BLA and increases c-Fos in serotonergic neurons within the rostral, mid-rostrocaudal, and caudal DR (Amat et al., ). Serotonin concentrations in the Acb are also modified by CRF receptor activation in the DR. Low doses of CRF (0.1 ug) injected into the DR, including both the DRD and DRV aspects of the mid-rostrocaudal DR, reduces 5-HT concentrations whereas higher doses (0.5 μg) increases 5-HT in the Acb (Lukkes et al., ). Importantly, a CRF1 receptor antagonist blocked the effect at the low dose while a CRF2 receptor antagonist blocked the effect of the high dose, showing that CRF is activating CRF1, perhaps on GABA interneurons, to inhibit 5-HT release while at higher concentrations is also activating CRF2 receptors, resulting in increased release of 5-HT in the Acb. These data show that direct activation of CRF receptors in the DR modulate 5-HT release in emotion-related brain regions.
The changes in 5-HT release in the BLA, CE, and Acb are associated with varying behavioral outputs related to emotion. Activation of 5-HT2C receptors in the BLA increases fear-like behaviors (Campbell and Merchant, ; Greenwood et al., ) which corresponds with the increased release of 5-HT seen in this brain region after CRF2 activation in the DR (Amat et al., ). Additionally, 5-HT receptor activation in the CE has also been implicated in increased anxiety and fear-like behaviors as increased 5-HT in the CE leads to increased freezing behavior (Forster et al., ), presumably through activation of the excitatory 5-HT2A/C receptors located in the CE (Asan et al., ). Further, foot shock has been shown to also increase 5-HT release in the Acb in association with freezing behavior, indicating a role for fear-like behavioral responses in relation to increased 5-HT release in the Acb (Fulford and Marsden, , ). It is not clear which 5-HT receptors in the Acb would be playing a role in fear-like behaviors. However, both 5-HT2A and5-HT2C receptors in this region have been shown to be involved in drug reward behavior, which can be modulated by stress (Erb and Stewart, ; Zayara et al., ). It is likely that increasing and decreasing 5-HT levels in various emotion-related brain regions involves a complex interplay of 5-HT receptors given that their binding can both inhibit and excite neuronal activation and 5-HT receptors have been shown on GABA neurons and glutamate neurons (Rainnie, ; Guo and Rainnie, ; Asan et al., ).
CRF, UCNs, and 5-HT interactions controlling emotional behavior
Numerous studies have demonstrated the involvement of members of the CRF family of peptides and their respective receptors and 5-HT in emotional behaviors in rodents. These include studies involving administration of specific CRF receptor agonists and antagonists with both i.c.v. and intra-DR applications as discussed above. Additionally, development of numerous mutant mice with genetic knock out (KO) or OE of one or more of these peptides or receptors have helped further our knowledge about the important role CRF plays in emotional behaviors (described below). Here, we will focus on behaviors that have been shown to involve the interactions between CRF, the UCNs, and 5-HT.
A number of studies have implicated CRF/5-HT interactions in control of emotional behavior. Administration of CRF through i.c.v increases the acoustic startle response and the CRF-induced startle is correlated with activation of c-Fos within the DR (Meloni et al., ). Partially, the c-Fos positive neurons were also positive for 5-HT and projected to the mPFC, a region that is important in the effects of controllability on behavioral consequences of stress (Rozeske et al., ; Patel et al., ). Behavioral consequences of uncontrollable stress are mediated by CRF receptors in the DR (Hammack et al., , ,). In particular, it has been shown that CRF2 receptors in the DRC are responsible for the behavioral consequences, observed 24 h later, of inescapable shock and that activation of CRF2 receptors in the DRC can mimic the effects of uncontrollable shock on behavior (Hammack et al., ). Further, activation of CRF1 receptors by low doses of CRF acts to inhibit the DR and can block the behavioral consequences of uncontrollable stress (Hammack et al., ). Stressors such as foot shock and restraint induce neuronal activation, as measured by c-Fos, in anxiety-related regions including the DR, amygdala, and BNST while at the same time also increasing mRNA for CRF in the BNST and CE, suggesting that anxiety- or fear-inducing stimuli alter CRF function while activating neurons in the DR (Funk et al., ). Importantly, this implicates a complex system that is responsive to the effects of an acute stressor, which can lead to alterations in emotional behaviors such as increased freezing behaviors (Hammack et al., ). These data thus suggest a crucial role of CRF receptors within the DR in control of stress-related behaviors and suggest that CRF/5-HT interactions are important in the behavioral consequences of uncontrollable stress.
Chronic activation of the CRF system is associated with changes in emotional behavior. Specifically, OE of CRF within the BNST does not produce basal changes in anxiety yet when induced prior to fear conditioning, it interferes with learning, while induction after fear conditioning but before fear testing produces an exaggerated fear response (Sink et al., ). Importantly, OE of CRF in the BNST results in changes in binding density for CRF1 in the BNST and CRF2 in the dorsal and caudal portions of the DR. This suggests that alterations of CRF expression in specific areas connected to the DR can lead to both physiological and emotional changes, depending on time points, and can disrupt fear learning or enhance fear expression, possibly through alterations in 5-HT function through decreased CRF2 receptors in the dorsal and caudal DR as these receptors have been shown to be involved in fear related behaviors (Hammack et al., ). Repeated administration of UCN 1 into the BLA has also been shown to induce serotonergic changes in the DR, including an increase in tph2 mRNA in specifically the DRVL that was correlated with increases in anxiety-like behavior (Donner et al., ). Further, maternal separation and later social defeat also serve to increase tph2 mRNA in the DRVL/VLPAG and produce a more passive-like coping behavior, and this increase in tph2 mRNA could serve as a common factor related to altered emotionality brought on by multiple environmental stressors (Gardner et al., , ). These studies suggest that the interaction between CRF receptor activation and 5-HT can modify emotional behavior while environmental experience can serve to alter 5-HT systems in a manner that is dependent on CRF receptor activation.
Interactions between CRF and serotonergic systems have also been implicated in control of active vs. passive behavioral coping responses during forced swim stress. The swim stress-induced reduction in 5-HT concentration in the lateral septum has been shown to be dependent on CRF receptor activation as an i.c.v. CRF1,2 receptor antagonist blocks this effect on 5-HT (Price et al., ). This effect may be specific to swim stress, however, as 5-HT concentrations increase in the lateral septum in mice in the presence of predator odor (Beekman et al., ). Further, the increase in 5-HT seen in the hippocampus during forced swim can also be blocked using a non-specific CRF antagonist given i.c.v. (Linthorst et al., ; Kagamiishi et al., ; De Groote et al., ). These studies suggest a role for CRF receptor activation in control of serotonergic systems by diverse stress-related stimuli.
CRF, UCN 1, 2, and 3, and CRF receptor transgenic animals, serotonergic systems, and emotional behavior
One line of research taken to investigate the roles of CRF, UCNs, and CRF receptors in control of serotonergic systems and emotional behavior is to use transgenic animals. Genes can be removed or added in to influence development from fertilization or can be conditionally changed after birth to avoid developmental alterations associated with transgenic manipulations that may lead to unintended consequences (Smith et al., ; Timpl et al., ). It is important to keep in mind as well-that many of these studies will produce essentially the overall sum effect of adding or removing peptides or receptors from the entire brain and peripheral systems on behavior and that further work with more selective changes will be informative as to their roles within specific brain regions.
Both CRF1 and CRF2 receptor KO mice have been developed and used to investigate the role of the receptors in control of emotional behaviors. The CRF1 receptor KO mice display a decrease in anxiety-like behaviors while CRF2 receptor KO mice tend to display an increase in anxiety and depression-like behaviors, although not in all cases or in all measures (Smith et al., ; Timpl et al., ; Bale et al., ; Coste et al., , ). In CRF1,2 receptor double KO mice, only males show an increase in anxiety-like behavior while the females tend to show normal or decreased anxiety, which suggests that there is an interaction between sex and genotype on anxiety-like behavioral output in these animals (Bale et al., ). The rearing behavior of heterozygous and homozygous CRF2 receptor KO dams seems supports an increase in anxiety-like behavior in their male offspring regardless of the males' genotype, implying that both environmental and genetic factors play a role in anxiety-like behaviors and that sex is an important factor (Bale et al., ). Further evidence suggests that CRF1 receptors in the limbic system specifically are important in controlling anxiety-like behaviors (Muller et al., ). Conditional KO of CRF1 receptors in the limbic system has no effect on the HPA axis, but results in reduced anxiety-like behavior and increased active coping in depression models (Muller et al., ). CRF1 receptors in the limbic system therefore seem to play a critical role in initiating an anxiety response.
Mouse models have also been developed to investigate the effects of OE or deletion of CRF. Chronic OE of CRF results in a downregulation of UCN 1 in the Edinger-Westphal nucleus (Kozicz et al., ) while CRF KO results in an upregulation of UCN 1 in the Edinger-Westphal nucleus, suggesting that CRF may control the level of UCN 1 expression or that changes in CRF can be compensated for by UCN 1 (Weninger et al., ). Moreover, CRF OE mice also show a change in CRF1 and CRF2 receptor mRNA expression throughout the brain (Korosi et al., ). In particular, OE of CRF induces a down-regulation of CRF1 receptors while at the same time it induces an upregulation of CRF2 receptors in the brain while the overall distribution of receptors remains the same showing that receptor mRNA expression is dependent on the level of CRF expression in these animals. CRF OE mice also show an increase in anxiety-like behavior, perhaps mediated in part by overactivation of CRF1 receptors or by the increase in CRF2 receptors in the DR (Korosi et al., ) and changes in responsiveness to alterations in 5-HT release in regions connected with the DR (Stenzel-Poore et al., ; Heinrichs et al., ; van Gaalen et al., ). These mouse models demonstrate that CRF KO or OE alters the expression of other members of the CRF family of neuropeptides and their receptors, implying that an overall increase or decrease of CRF or the UCNs can contribute to changes in receptor expression and alter behavioral output.
Chronic OE of UCN 3 is associated with changes in the serotonergic system and altered emotion-like behaviors. Chronic OE of UCN 3 produces a change in post-stress 5-HT and 5-HIAA concentrations in the caudal and dorsal DR and lateral septum as well as a basal change in 5-HT1A receptor mRNA in both the DR and amygdala (Neufeld-Cohen et al., ). UCN 3 OE also alters basal anxiety-related behavior compared to wild type animals (Neufeld-Cohen et al., ), which may implicate desensitized CRF2 receptors resulting in the increased anxiety, similar to the CRF2 receptor KO mice. In particular, UCN 3 OE mice have increased anxiety-like behavior in both the elevated plus-maze and the light-dark box and an increase in immobility in the tail suspension test suggesting that chronic CRF2 receptor activation results in a basal increase in emotionality. Consistent with these data, conditional OE of UCN 3 in the rostral portion of the perifornical area, where UCN 3 is normally expressed, also increases anxiety-like behavior (Kuperman et al., ). Interestingly, post-stress anxiety-like behavior in UCN 3 OE mice is either not increased or is in fact reduced suggesting that chronic activation of CRF2 receptors creates a chronic anxiety-like state but resistance to further stress-induced anxiety (Neufeld-Cohen et al., ).
A number of studies have also investigated the role of UCN 1, 2, and 3 in emotional behaviors using transgenic mice. UCN 1 KO mice have been shown to have normal anxiety-like behavior although a decrease in the acoustic startle response is seen in males (Wang et al., ) and a lower startle response has been associated with decreased anxiety in other measures of anxiety (Salam et al., ). These animals are described as having normal hearing although another line of UCN 1 KO mice appeared to have disruption of hearing and an increase in anxiety-like behavior (Vetter et al., ) so a reduced startle response maybe due do a disruption in the startle neuronal pathway. Both UCN 2 and 3 KO animals do not show any disruption in anxiety-like behaviors, although reduced aggressiveness is seen in male UCN 2 KO's and reduced depression-like behaviors were noted in female UCN 2 KO mice (Chen et al., ; Deussing et al., ; Breu et al., ). However, given that both CRF and UCN's can activate CRF2 receptors, it is not surprising that there is not a noticeable change in anxiety or consistent decrease in depression-like behaviors in the UCN 2 or 3 KO mice. A double KO of UCN 1 and 2, however, results in a anxiolytic-like phenotype (Neufeld-Cohen et al., ) while UCN triple KO mice show normal basal anxiety levels but increased anxiety-like behavior 24 h after a stressor (Neufeld-Cohen et al., ). Notably, the UCN triple KO mice show some basal and 24 h post-stress differences in serotonergic activities in the amygdala, subiculum and medial and later septum, which is consistent with the hypothesis that the increase in anxiety-like behavior is mediated in part by changes in serotonin and implicates a role for CRF2 receptor activation in controlling 5-HT and its potential role during the stress recovery period.
Non-human primate data on CRF/5-HT interactions and emotional behavior
Non-human primate data gives further insight into the interaction between CRF, serotonergic systems, and emotional behavior. Recent data suggest that, in a particular subset of cynomolgus macaques deemed to be more stress-sensitive than their cohorts because of interrupted menstrual cycles, chronic treatment with a serotonin selective reuptake inhibitor (SSRI) produces significant changes in CRF receptors after 15-weeks of administration but not in less-stress sensitive animals (Senashova et al., ). Specifically, after chronic treatment with an SSRI, the stress sensitive monkeys had an increased number of CRF2 receptor mRNA positive cells as found through digoxigenin-in situ hybridization staining, compared to less stress-sensitive monkeys. Similar studies have shown that the stress-sensitive monkeys have an increased cortisol response to serotonin release induced by fenfluramine while showing a blunted prolactin release (Bethea et al., ) and basal increased cortisol release during the day (Herod et al., ,), suggesting further disruption in normal serotonin systems. Interestingly, these monkeys, along with the altered CRF receptors in response to an SSRI, also have lowered CRF fiber density in the DR with an increased number of UCN 1 cell bodies after SSRI treatment (Weissheimer et al., ). This suggests that altered levels of CRF and UCN 1 contribute to the stress sensitivity witnessed in the animals and that altered 5-HT systems contribute to these differences, perhaps through increased CRF or decreased UCN signaling to the DR. In fact, stress-sensitive cynomolgus macaques, compared to less stress sensitive cynomolgus macaques, have decreased serotonin transporter and tryptophan hydroxylase 2 (TPH) mRNA and, in one study, had lower 5-HT1A receptor mRNA in the DR, all suggesting that alterations in these 5-HT systems contribute along with the altered CRF/UCN system to the stress-sensitive phenotype of these monkeys (Bethea et al., ; Lima et al., ).
Clinical data on CRF/5-HT interactions and emotional behavior
There is a wealth of knowledge gained from studies showing that SSRI's can be a useful way to treat anxiety and depression (Goldstein and Goodnick, ) although a meta-analysis of clinical data also show that this may be dependent on the severity of the disorder and less useful in mild to moderate depression (Fournier et al., ) although see (Gibbons et al., ). There has also been interest in modulating CRF in patients with affective disorders to help alleviate their symptoms (Künzel et al., ). Corticotropin-releasing factor-positive terminals are apposed to serotonergic neurons in the human brain suggesting that they play a role in modulating 5-HT as seen in animal models (Ruggiero et al., ). Importantly, elevated CRF concentrations have been described in the cerebral spinal fluid in suicide victims, suggesting a dysregulation of the central CRF system (Arató et al., ). Although the data have not been completely consistent in findings of elevated CRF concentrations, with reports of no difference or even decreased CRF in CSF, it does appear that there can be abnormal levels of CRF in CSF in people with depression and the discrepancies may represent subgroups of depression or perhaps how long they have been in the episode of depression (Mitchell, ). One study of interest concerning the interplay between CRF and 5-HT showed elevated levels of CRF in CSF which subsequently normalized after treatment with the SSRI fluoxetine, suggesting that the abnormality in 5-HT function in depression could be related to the elevation of CRF (De Bellis et al., ).
Depression has also been associated with alterations in 5-HT function in specific regions of the DR in humans. Data collected from postmortem human brain tissue show an increase in TPH immunoreactivity (Underwood et al., ; Boldrini et al., ) and mRNA (Bach-Mizrachi et al., , ) in the DR of depressed suicides, with a more pronounced increase in the DRC. Data also show an increase of TPH immunoreactivity specifically in the DRD of depressed alcoholic suicides (Bonkale et al., ) with a trend for an increase in tph2 mRNA expression in the same region in non-alcoholic depressed suicides (Bach-Mizrachi et al., ). These data are in contrast to those described in the stress-sensitive monkeys in which it had been found that there is decreased tph2 mRNA compared to less stress sensitive monkeys, which may indicate that there are multiple pathways leading to emotion-related disorders (Bethea et al., ). In male, but not female, suicide victims, UCN mRNA is significantly elevated in the Edinger-Westphal nucleus (Kozicz et al., ) further implicating a disruption in central CRF-related peptides related to depression. Other data show that CRF is upregulated as well in the DR and MnR in depressed suicides providing direct evidence for changes in CRF in brain regions that are the major sources for 5-HT in humans, which could be one reason for the altered TPH seen in other studies, perhaps through increased activation of serotonergic neurons by CRF (Austin et al., ).
Conclusions
Corticotropin releasing factor and the UCNs interact with serotonergic systems in a topographically organized manner and, depending on the receptor and the connectivity with limbic brain regions and concentrations of peptide, can lead to alterations in gene expression, changes in serotonergic output, and increased or decreased emotional behaviors. Focus on the relationship between the members of the CRF family of peptides and serotonergic systems should take into consideration the complex topographical organization of serotonergic systems. Increased understanding of these relationships in specific brain regions could lead to novel therapeutic strategies to more directly modulate emotional outcomes with fewer side effects relative to current treatments for anxiety and affective disorders.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Statements
Acknowledgments
Christopher A. Lowry receives grant support from the National Institute of Mental Health (R01MH065702, R01MH086539, R01DA019921, R01MH075968), the National Science Foundation (NSF-IOS 0921969), the Depressive and Bipolar Disorder Alternative Treatment Foundation, and is the recipient of an NSF CAREER Award (NSF-IOS 0845550) and a NARSAD, Brain and Behavior Research Foundation 2010 Young Investigator Award. He reports the following activities for the previous two years: consultant for Enlight Biosciences. Preparation of this manuscript was supported by an award from the National Institute of Mental Health (R01MH086539).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AbramsJ. K.JohnsonP. L.Hay-SchmidtA.MikkelsenJ. D.ShekharA.LowryC. A. (2005). Serotonergic systems associated with arousal and vigilance behaviors following administration of anxiogenic drugs. Neuroscience133, 983–997. 10.1016/j.neuroscience.2005.03.025
2
AltieriS. C.Garcia-GarciaA. L.LeonardoE. D.AndrewsA. M. (2012). Rethinking 5-HT1A Receptors: emerging modes of inhibitory feedback of relevance to emotion-related behavior. ACS Chem. Neurosci. 4, 72–83. 10.1021/cn3002174
3
AlvesS. H.PinheiroG.MottaV.Landeira-FernandezJ.CruzA. P. (2004). Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but not dorsal hippocampus. Behav. Pharmacol. 15, 37–43. 10.1097/00008877-200402000-00005
4
AmatJ.BarattaM. V.PaulE.BlandS. T.WatkinsL. R.MaierS. F. (2005). Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat. Neurosci. 8, 365–371. 10.1038/nn1399
5
AmatJ.TamblynJ. P.PaulE. D.BlandS. T.AmatP.FosterA. C.et al. (2004). Microinjection of urocortin 2 into the dorsal raphe nucleus activates serotonergic neurons and increases extracellular serotonin in the basolateral amygdala. Neuroscience129, 509–519. 10.1016/j.neuroscience.2004.07.052
6
AratóM.BánkiC. M.BissetteG.NemeroffC. B. (1989). Elevated CSF CRF in suicide victims. Biol. Psychiatry25, 355–359. 10.1016/0006-3223(89)90183-2
7
AsanE.SteinkeM.LeschK.-P. (2013). Serotonergic innervation of the amygdala: targets, receptors, and implications for stress and anxiety. Histochem. Cell Biol. 139, 785–813. 10.1007/s00418-013-1081-1
8
AustinM. C.JanoskyJ. E.MurphyH. A. (2003). Increased corticotropin-releasing hormone immunoreactivity in monoamine-containing pontine nuclei of depressed suicide men. Mol. Psychiatry8, 324–332. 10.1038/sj.mp.4001250
9
AzmitiaE. C.SegalM. (1978). An autoradiographic analysis of the differential ascending projection of the dorsal and median raphe nuclei in the rat. J. Comp. Neurol. 179, 651–668. 10.1002/cne.901790311
10
Bach-MizrachiH.UnderwoodM. D.KassirS. A.BakalianM. J.SibilleE.TamirH.et al. (2006). Neuronal tryptophan hydroxylase mRNA expression in the human dorsal and median raphe nuclei: major depression and suicide. Neuropsychopharmacology31, 814–824. 10.1038/sj.npp.1300897
11
Bach-MizrachiH.UnderwoodM. D.TinA.EllisS. P.MannJ. J.ArangoV. (2008). Elevated expression of tryptophan hydroxylase-2 mRNA at the neuronal level in the dorsal and median raphe nuclei of depressed suicides. Mol. Psychiatry13, 507–513. 10.1038/sj.mp.4002143
12
BagoM.MarsonL.DeanC. (2002). Serotonergic projections to the rostroventrolateral medulla from midbrain and raphe nuclei. Brain Res. 945, 249–258. 10.1016/S0006-8993(02)02811-1
13
BaleT. L.ContarinoA.SmithG. W.ChanR.GoldL. H.SawchenkoP. E.et al. (2000). Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genet. 24, 410–414. 10.1038/74263
14
BaleT. L.PicettiR.ContarinoA.KoobG. F.ValeW. W.LeeK.-F. (2002). Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like Behavior. J. Neurosci. 22, 193–199.
15
BarnesN. M.SharpT. (1999). A review of central 5-HT receptors and their function. Neuropharmacology38, 1083–1152. 10.1016/S0028-3908(99)00010-6
16
BeekmanM.FlachskammC.LinthorstA. C. E. (2005). Effects of exposure to a predator on behaviour and serotonergic neurotransmission in different brain regions of C57bl/6N mice. Eur. J. Neurosci. 21, 2825–2836. 10.1111/j.1460-9568.2005.04107.x
17
BeitzA. J. (1982). The organization of afferent projections to the midbrain periaqueductal gray of the rat. Neuroscience7, 133–159. 10.1016/0306-4522(82)90157-9
18
BetheaC. L.LimaF. B.CentenoM. L.WeissheimerK. V.SenashovaO.ReddyA. P.et al. (2011). Effects of citalopram on serotonin and CRF systems in the midbrain of primates with differences in stress sensitivity. J. Chem. Neuroanat. 41, 200–218. 10.1016/j.jchemneu.2011.05.010
19
BetheaC. L.PauF. K. Y.FoxS.HessD. L.BergaS. L.CameronJ. L. (2005a). Sensitivity to stress-induced reproductive dysfunction linked to activity of the serotonin system. Fertil. Steril. 83, 148–155. 10.1016/j.fertnstert.2004.06.051
20
BetheaC. L.StreicherJ. M.MirkesS. J.SanchezR. L.ReddyA. P.CameronJ. L. (2005b). Serotonin-related gene expression in female monkeys with individual sensitivity to stress. Neuroscience132, 151–166. 10.1016/j.neuroscience.2004.11.022
21
BinderE. B.NemeroffC. B. (2010). The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol. Psychiatry15, 574–588. 10.1038/mp.2009.141
22
BittencourtJ. C.SawchenkoP. E. (2000). Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system. J. Neurosci. 20, 1142–1156.
23
BittencourtJ. C.VaughanJ.AriasC.RissmanR. A.ValeW. W.SawchenkoP. E. (1999). Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 crf receptors. J. Comp. Neurol. 415, 285–312. 10.1002/(SICI)1096-9861(19991220)415:3<285::AID-CNE1>3.0.CO;2-0
24
BoldriniM.UnderwoodM. D.MannJ. J.ArangoV. (2005). More tryptophan hydroxylase in the brainstem dorsal raphe nucleus in depressed suicides. Brain Res. 1041, 19–28. 10.1016/j.brainres.2005.01.083
25
BonkaleW. L.TureckiG.AustinM. C. (2006). Increased tryptophan hydroxylase immunoreactivity in the dorsal raphe nucleus of alcohol-dependent, depressed suicide subjects is restricted to the dorsal subnucleus. Synapse60, 81–85. 10.1002/syn.20278
26
BouwknechtJ. A.SpigaF.StaubD. R.HaleM. W.ShekharA.LowryC. A. (2007). Differential effects of exposure to low-light or high-light open-field on anxiety-related behaviors: relationship to c-Fos expression in serotonergic and non-serotonergic neurons in the dorsal raphe nucleus. Brain Res. Bull. 72, 32–43. 10.1016/j.brainresbull.2006.12.009
27
BreuJ.ToumaC.HölterS. M.KnapmanA.WurstW.DeussingJ. M. (2012). Urocortin 2 modulates aspects of social behaviour in mice. Behav. Brain Res. 233, 331–336. 10.1016/j.bbr.2012.05.031
28
CalandreauL.JaffardR.DesmedtA. (2007). Dissociated roles for the lateral and medial septum in elemental and contextual fear conditioning. Learn. Mem. 14, 422–429. 10.1101/lm.531407
29
CampbellB. M.MerchantK. M. (2003). Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res. 993, 1–9. 10.1016/S0006-8993(03)03384-5
30
CanterasN. S.Shammah-LagnadoS. J.SilvaB. A.RicardoJ. A. (1990). Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat. Brain Res. 513, 43–59. 10.1016/0006-8993(90)91087-W
31
ChalmersD.LovenbergT.De SouzaE. (1995). Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J. Neurosci. 15, 6340–6350.
32
CheetaS.KennyP. J.FileS. E. (2000). Hippocampal and septal injections of nicotine and 8-OH-DPAT distinguish among different animal tests of anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry24, 1053–1067. 10.1016/S0278-5846(00)00129-9
33
ChenA.ZorrillaE.SmithS.RoussoD.LevyC.VaughanJ.et al. (2006). Urocortin 2-deficient mice exhibit gender-specific alterations in circadian hypothalamus-pituitary-adrenal axis and depressive-like behavior. J. Neurosci. 26, 5500–5510. 10.1523/JNEUROSCI.3955-05.2006
34
CommonsK. G.ConnolleyK. R.ValentinoR. J. (2003). A neurochemically distinct dorsal raphe-limbic circuit with a potential role in affective disorders. Neuropsychopharmacology28, 206–215. 10.1038/sj.npp.1300045
35
CosteS. C.HeardA. D.PhillipsT. J.Stenzel-PooreM. P. (2006). Corticotropin-releasing factor receptor type 2-deficient mice display impaired coping behaviors during stress. Genes Brain Behav. 5, 131–138. 10.1111/j.1601-183X.2005.00142.x
36
CosteS. C.KestersonR. A.HeldweinK. A.StevensS. L.HeardA. D.HollisJ. H.et al. (2000). Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat. Genet. 24, 403–409. 10.1038/74255
37
DautzenbergF. M.KilpatrickG. J.HaugerR. L.MoreauJ.-L. (2001). Molecular biology of the CRH receptors— in the mood. Peptides22, 753–760. 10.1016/S0196-9781(01)00388-6
38
DavisM. (1997). Neurobiology of fear responses: the role of the amygdala. J. Neuropsychiatry Clin. Neurosci. 9, 382–402.
39
DavisM.WalkerD.MilesL. A.GrillonC. (2010). Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacology35, 105–135. 10.1038/npp.2009.109
40
DayH. E.GreenwoodB. N.HammackS. E.WatkinsL. R.FleshnerM.MaierS. F.et al. (2004). Differential expression of 5HT-1A, α1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, γ-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. J. Comp. Neurol. 3, 364–378. 10.1002/cne.20138
41
De BellisM. D.GoldP. W.GeraciotiT. D. J.ListwakS. J.KlingM. A. (1993). Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiatry150, 656–657.
42
De GrooteL.PeñalvaR. G.FlachskammC.ReulJ. M. H. M.LinthorstA. C. E. (2005). Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists. J. Neurochem. 94, 45–56. 10.1111/j.1471-4159.2005.03164.x
43
de PaulaD. C.TorricelliA. S.LopreatoM. R.NascimentoJ. O. G.VianaM. B. (2012). 5-HT2A receptor activation in the dorsolateral septum facilitates inhibitory avoidance in the elevated T-maze. Behav. Brain Res. 226, 50–55. 10.1016/j.bbr.2011.08.044
44
DeussingJ. M.BreuJ.KühneC.KallnikM.BunckM.GlaslL.et al. (2010). Urocortin 3 modulates social discrimination abilities via corticotropin-releasing hormone receptor type 2. J. Neurosci. 30, 9103–9116. 10.1523/JNEUROSCI.1049-10.2010
45
DonaldsonC. J.SuttonS. W.PerrinM. H.CorriganA. Z.LewisK. A.RivierJ. E.et al. (1996). Cloning and characterization of human urocortin. Endocrinology137, 2167–2170. 10.1210/en.137.5.2167
46
DongH. W.PetrovichG. D.SwansonL. W. (2001). Topography of projections from amygdala to bed nuclei of the stria terminalis. Brain Res. Brain Res. Rev. 38, 192–246. 10.1016/S0165-0173(01)00079-0
47
DongH. W.SwansonL. W. (2004). Organization of axonal projections from the anterolateral area of the bed nuclei of the stria terminalis. J. Comp. Neurol. 468, 277–298. 10.1002/cne.10949
48
DonnerN.JohnsonP.FitzS.KellenK.ShekharA.LowryC. (2012a). Elevated tph2 mRNA expression in a rat model of chronic anxiety. Depress. Anxiety. 29, 307–319. 10.1002/da.21925
49
DonnerN. C.MontoyaC. D.LukkesJ. L.LowryC. A. (2012b). Chronic non-invasive corticosterone administration abolishes the diurnal pattern of tph2 expression. Psychoneuroendocrinology37, 645–661. 10.1016/j.psyneuen.2011.08.008
50
DunnA. J.BerridgeC. W. (1990). Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses?Brain Res. Brain Res. Rev. 15, 71–100. 10.1016/0165-0173(90)90012-D
51
ErbS.StewartJ. (1999). A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin-releasing factor on stress-induced reinstatement of cocaine seeking. J. Neurosci. 19, 35RC.
52
ErikssonT. M.HolstS.StanT. L.HagerT.SjögrenB.ÖgrenS. O.et al. (2012). 5-HT1A and 5-HT7 receptor crosstalk in the regulation of emotional memory: implications for effects of selective serotonin reuptake inhibitors. Neuropharmacology63, 1150–1160. 10.1016/j.neuropharm.2012.06.061
53
FeinsteinJ. S.BuzzaC.HurlemannR.FollmerR. L.DahdalehN. S.CoryellW. H.et al. (2013). Fear and panic in humans with bilateral amygdala damage. Nat. Neurosci. 16, 270–272. 10.1038/nn.3323
54
FeketeÉ. M.ZorrillaE. P. (2007). Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front. Neuroendocrinol. 28, 1–27. 10.1016/j.yfrne.2006.09.002
55
ForsterG. L.FengN.WattM. J.KorzanW. J.MouwN. J.SummersC. H.et al. (2006). Corticotropin-releasing factor in the dorsal raphe elicits temporally distinct serotonergic responses in the limbic system in relation to fear behavior. Neuroscience141, 1047–1055. 10.1016/j.neuroscience.2006.04.006
56
FournierJ. C.DeRubeisR. J.HollonS. D.DimidjianS.AmsterdamJ. D.SheltonR. C.et al. (2010). Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA303, 47–53. 10.1001/jama.2009.1943
57
FulfordA. J.MarsdenC. A. (1997). Conditioned release of 5-hydroxytryptamine in vivo in the nucleus accumbens following isolation-rearing in the rat. Neuroscience83, 481–487. 10.1016/S0306-4522(97)00423-5
58
FulfordA. J.MarsdenC. A. (2007). An intact dopaminergic system is required for context-conditioned release of 5-HT in the nucleus accumbens of postweaning isolation-reared rats. Neuroscience149, 392–400. 10.1016/j.neuroscience.2007.08.002
59
FunkD.LiZ.LêA. D. (2006). Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: relationship to the reinstatement of alcohol seeking. Neuroscience138, 235–243. 10.1016/j.neuroscience.2005.10.062
60
GardnerK. L.HaleM. W.OldfieldS.LightmanS. L.PlotskyP. M.LowryC. A. (2009). Adverse experience during early life and adulthood interact to elevate tph2 mRNA expression in serotonergic neurons within the dorsal raphe nucleus. Neuroscience163, 991–1001. 10.1016/j.neuroscience.2009.07.055
61
GardnerK. L.ThrivikramanK. V.LightmanS. L.PlotskyP. M.LowryC. A. (2005). Early life experience alters behavior during social defeat: focus on serotonergic systems. Neuroscience136, 181–191. 10.1016/j.neuroscience.2005.07.042
62
GibbonsR. D.HurK.BrownC.DavisJ. M.MannJ. (2012). Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch. Gen. Psychiatry69, 572–579. 10.1001/archgenpsychiatry.2011.2044
63
GoetzR. R.KleinD. F.PappL. A.MartinezJ. M.GormanJ. M. (2001). Acute panic inventory symptoms during CO2 inhalation and room-air hyperventilation among panic disorder patients and normal controls. Depress. Anxiety14, 123–136. 10.1002/da.1054
64
GoldsteinB. J.GoodnickP. J. (1998). Selective serotonin reuptake inhibitors in the treatment of affective disorders–III. Tolerability, safety and pharmacoeconomics. J. Psychopharmacol. 12(3 Suppl. B), S55–S87.
65
GrayT. S. (1993). Amygdaloid CRF pathways: role in autonomic, neuroendocrine, and behavioral responses to stress. Ann. NY. Acad. Sci. 697, 53–60
66
GreenwoodB.FoleyT. E.DayH.BurhansD.BrooksL.CampaeuS.et al. (2005). Wheel running alters serotonin (5-HT) transporter, 5-HT(1a), 5-HT(1b), and alpha(1b)-adrenergic receptor mRNA in the rat raphe nuclei. Biol. Psychiatry57, 559–568. 10.1016/j.biopsych.2004.11.025
67
GreenwoodB.FoleyT. E.DayH. E.CampisiJ.HammackS. H.CampeauS.et al. (2003). Freewheel running prevents learned helplessness/behavioral depression: role of dorsal raphe serotonergic neurons. J. Neurosci. 23, 2889–2898.
68
GreenwoodB. N.StrongP. V.LoughridgeA. B.DayH. E. W.ClarkP. J.MikaA.et al. (2012). 5-HT2C receptors in the basolateral amygdala and dorsal striatum are a novel target for the anxiolytic and antidepressant effects of exercise. PLoS ONE7:e46118. 10.1371/journal.pone.0046118
69
GroveE. A. (1998). Neural associations of the substantia innominata in the rat: afferent connections. J. Comp. Neurol. 15, 35–46.
70
GuoJ. D.HammackS. E.HazraR.LevitaL.RainnieD. G. (2009). Bi-directional modulation of bed nucleus of stria terminalis neurons by 5-HT: molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience164, 1776–1793. 10.1016/j.neuroscience.2009.09.028
71
GuoJ. D.RainnieD. G. (2010). Presynaptic 5-HT1B receptor-mediated serotonergic inhibition of glutamate transmission in the bed nucleus of the stria terminalis. Neuroscience165, 1390–1401. 10.1016/j.neuroscience.2009.11.071
72
HaleM.ShekharA.LowryC. (2012). Stress-related serotonergic systems: implications for symptomatology of anxiety and affective disorders. Cell. Mol. Neurobiol. 32, 695–708. 10.1007/s10571-012-9827-1
73
HaleM. W.DadyK. F.EvansA. K.LowryC. A. (2011). Evidence for in vivo thermosensitivity of serotonergic neurons in the rat dorsal raphe nucleus and raphe pallidus nucleus implicated in thermoregulatory cooling. Exp. Neurol. 227, 264–278. 10.1016/j.expneurol.2010.11.012
74
HaleM. W.Hay-SchmidtA.MikkelsenJ. D.PoulsenB.BouwknechtJ. A.EvansA. K.et al. (2008). Exposure to an open-field arena increases c-Fos expression in a subpopulation of neurons in the dorsal raphe nucleus, including neurons projecting to the basolateral amygdaloid complex. Neuroscience157, 733–748. 10.1016/j.neuroscience.2008.09.050
75
HaleM. W.LowryC. A. (2011). Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits. Psychopharmacology213, 243–264. 10.1007/s00213-010-2089-z
76
HaleM. W.StamperC. E.StaubD. R.LowryC. A. (2010). Urocortin 2 increases c-Fos expression in serotonergic neurons projecting to the ventricular/periventricular system. Exp. Neurol. 224, 271–281. 10.1016/j.expneurol.2010.04.002
77
HammackS. E.GuoJ.-D.HazraR.DabrowskaJ.MyersK. M.RainnieD. G. (2009). The response of neurons in the bed nucleus of the stria terminalis to serotonin: implications for anxiety. Prog. Neuropsychopharmacol. Biol. Psychiatry33, 1309–1320. 10.1016/j.pnpbp.2009.05.013
78
HammackS. E.PepinJ. L.DesMarteauJ. S.WatkinsL. R.MaierS. F. (2003a). Low doses of corticotropin-releasing hormone injected into the dorsal raphe nucleus block the behavioral consequences of uncontrollable stress. Behav. Brain Res. 147, 55–64. 10.1016/S0166-4328(03)00133-5
79
HammackS. E.SchmidM. J.LoPrestiM. L.Der-AvakianA.PellymounterM. A.FosterA. C.et al. (2003b). Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J. Neurosci. 23, 1019–1025.
80
HammackS. E.RicheyK. J.SchmidM. J.LoPrestiM. L.WatkinsL. R.MaierS. F. (2002). The role of corticotropin-releasing hormone in the dorsal raphe nucleus in mediating the behavioral consequences of uncontrollable stress. J. Neurosci. 22, 1020–1026.
81
HammackS. E.RicheyK. J.WatkinsL. R.MaierS. F. (2004). Chemical lesion of the bed nucleus of the stria terminalis blocks the behavioral consequences of uncontrollable stress. Behav. Neurosci. 118, 443–448. 10.1037/0735-7044.118.2.443
82
HannonJ.HoyerD. (2008). Molecular biology of 5-HT receptors. Behav. Brain Res. 195, 198–213. 10.1016/j.bbr.2008.03.020
83
HeinrichsS. C.MinH.TamrazS.CarmouchéM.BoehmeS. A.ValeW. W. (1997). Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology22, 215–224. 10.1016/S0306-4530(97)00030-9
84
HerodS. M.DettmerA. M.NovakM. A.MeyerJ. S.CameronJ. L. (2011a). Sensitivity to stress-induced reproductive dysfunction is associated with a selective but not a generalized increase in activity of the adrenal axis. Am. J. Physiol. Endocrinol. Metab. 300, E28–E36. 10.1152/ajpendo.00223.2010
85
HerodS. M.PohlC. R.CameronJ. L. (2011b). Treatment with a CRH-R1 antagonist prevents stress-induced suppression of the central neural drive to the reproductive axis in female macaques. Am. J. Physiol. Endocrinol. Metab. 300, E19–E27. 10.1152/ajpendo.00224.2010
86
HollisJ. H.EvansA. K.BruceK. P. E.LightmanS. L.LowryC. A. (2006). Lipopolysaccharide has indomethacin-sensitive actions on Fos expression in topographically organized subpopulations of serotonergic neurons. Brain Behav. Immun. 20, 569–577. 10.1016/j.bbi.2006.01.006
87
HolstegeG. (1995). The Basic, Somatic, and Emotional Components of the Motor System in Mammals. Vol. 137–154.San Diego, CA: Academic.
88
HoyerD.ClarkeD. E.FozardJ. R.HartigP. R.MartinG. R.MylecharaneE. J.et al. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157–203.
89
HoyerD.HannonJ. P.MartinG. R. (2002). Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. 71, 533–554. 10.1016/S0091-3057(01)00746-8
90
HurleyK. M.HerbertH.MogaM. M.SaperC. B. (1991). Efferent projections of the infralimbic cortex of the rat. J. Comp. Neurol. 308, 249–276. 10.1002/cne.903080210
91
ImaiH.SteindlerD. A.KitaiS. T. (1986). The organization of divergent axonal projections from the midbrain raphe nuclei in the rat. J. Comp. Neurol. 243, 363–380. 10.1002/cne.902430307
92
JohnsonP.LowryC.TruittW.ShekharA. (2008). Disruption of GABAergic tone in the dorsomedial hypothalamus attenuates responses in a subset of serotonergic neurons in the dorsal raphe nucleus following lactate-induced panic. J. Psychopharmacol. 22, 642–652. 10.1177/0269881107082900
93
JohnsonP. L.HollisJ. H.MoratallaR.LightmanS. L.LowryC. A. (2005). Acute hypercarbic gas exposure reveals functionally distinct subpopulations of serotonergic neurons in rats. J. Psychopharmacol. 19, 327–341. 10.1177/0269881105053281
94
KagamiishiY.YamamotoT.WatanabeS. (2003). Hippocampal serotonergic system is involved in anxiety-like behavior induced by corticotropin-releasing factor. Brain Res. 991, 212–221. 10.1016/j.brainres.2003.08.021
95
KazakovV. N.KravtsovP. Y.KrakhotkinaE. D.MaiskyV. A. (1993). Sources of cortical, hypothalamic and spinal serotonergic projections: topical organization within the nucleus raphe dorsalis. Neuroscience56, 157–164. 10.1016/0306-4522(93)90570-6
96
KellyK. J.DonnerN. C.HaleM. W.LowryC. A. (2011). Swim stress activates serotonergic and nonserotonergic neurons in specific subdivisions of the rat dorsal raphe nucleus in a temperature-dependent manner. Neuroscience197, 251–268. 10.1016/j.neuroscience.2011.09.011
97
KermanI. A.ShabrangC.TaylorL.AkilH.WatsonS. J. (2006). Relationship of presympathetic-premotor neurons to the serotonergic transmitter system in the rat brainstem. J. Comp. Neurol. 499, 882–896. 10.1002/cne.21129
98
KimM.-A.LeeH. S.LeeB. Y.WaterhouseB. D. (2004). Reciprocal connections between subdivisions of the dorsal raphe and the nuclear core of the locus coeruleus in the rat. Brain Res. 1026, 56–67. 10.1016/j.brainres.2004.08.022
99
KirbyL. G.RiceK. C.ValentinoR. J. (2000). Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology22, 148–162. 10.1016/S0893-133X(99)00093-7
100
KirifidesM. L.SimpsonK. L.LinR. C. S.WaterhouseB. D. (2001). Topographic organization and neurochemical identity of dorsal raphe neurons that project to the trigeminal somatosensory pathway in the rat. J. Comp. Neurol. 435, 325–340. 10.1002/cne.1033
101
KohlerC.Chan-PalayV.SteinbuschH. W. M. (1982). The distribution and origin of serotonin-containing fibers in the septal area: a combined immunohistochemical and fluorescent retrograde tracing study in the rat. J. Comp. Neurol. 209, 91–111. 10.1002/cne.902090109
102
KohlerC.SteinbuschH. W. M. (1982). Identification of serotonin and non-serotonin-containing neurons of the mid-brain raphe projecting to the entorhinal area and the hippocampal formation. A combined immunohistochemical and fluorescent retrograde tracing study in the rat brain. Neuroscience7, 951–975. 10.1016/0306-4522(82)90054-9
103
KorosiA.VeeningJ. G.KoziczT.HenckensM.DederenJ.GroeninkL.et al. (2006). Distribution and expression of CRF receptor 1 and 2 mRNAs in the CRF over-expressing mouse brain. Brain Res. 1072, 46–54. 10.1016/j.brainres.2005.12.034
104
KoziczT. (2007). On the role of urocortin 1 in the non-preganglionic Edinger–Westphal nucleus in stress adaptation. Gen. Comp. Endocrinol. 153, 235–240. 10.1016/j.ygcen.2007.04.005
105
KoziczT.KorosiA.KorsmanC.Tilburg-OuwensD.GroeninkL.VeeningJ.et al. (2004). Urocortin expression in the Edinger-Westphal nucleus is down-regulated in transgenic mice over-expressing neuronal corticotropin-releasing factor. Neuroscience123, 589–594. 10.1016/j.neuroscience.2003.10.042
106
KoziczT.Tilburg-OuwensD.FaludiG.PalkovitsM.RoubosE. (2008). Gender-related urocortin 1 and brain-derived neurotrophic factor expression in the adult human midbrain of suicide victims with major depression. Neuroscience152, 1015–1023. 10.1016/j.neuroscience.2007.12.050
107
KoziczT.YanaiharaH.ArimuraA. (1998). Distribution of urocortin-like immunoreactivity in the central nervous system of the rat. J. Comp. Neurol. 391, 1–10. 10.1002/(SICI)1096-9861(19980202)391:1<1::AID-CNE1>3.0.CO;2-6
108
KroutK. E.BelzerR. E.LoewyA. D. (2002). Brainstem projections to midline and intralaminar thalamic nuclei of the rat. J. Comp. Neurol. 448, 53–101. 10.1002/cne.10236
109
KünzelH. E.ZobelA. W.NickelT.AcklN.UhrM.SonntagA.et al. (2003). Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects. J. Psychiatr. Res. 37, 525–533. 10.1016/S0022-3956(03)00070-0
110
KupermanY.IsslerO.RegevL.MusseriI.NavonI.Neufeld-CohenA.et al. (2010). Perifornical Urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis. Proc. Natl. Acad. Sci. U.S.A. 107, 8393–8398. 10.1073/pnas.1003969107
111
LeeH. S.EumY. J.JoS. M.WaterhouseB. D. (2007). Projection patterns from the amygdaloid nuclear complex to subdivisions of the dorsal raphe nucleus in the rat. Brain Res. 1143, 116–125. 10.1016/j.brainres.2007.01.081
112
LeeH. S.KimM.-A.ValentinoR. J.WaterhouseB. D. (2003). Glutamatergic afferent projections to the dorsal raphe nucleus of the rat. Brain Res. 963, 57–71. 10.1016/S0006-8993(02)03841-6
113
LevitaL.HammackS. H.ManiaI.LiX.-Y.DavisM.RainnieD. G. (2004). 5-hydroxytryptamine 1A- like receptor activation in the bed nucleus of the stria terminalis: elctrophysiological and behaviroal studies. Neuroscience128, 583–596. 10.1016/j.neuroscience.2004.06.037
114
LewisK.LiC.PerrinM. H.BlountA.KunitakeK.DonaldsonC.et al. (2001). Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98, 7570–7575. 10.1073/pnas.121165198
115
LiC.VaughanJ.SawchenkoP. E.ValeW. W. (2002). Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J. Neurosci. 22, 991–1001.
116
LiQ.LuoT.JiangX.WangJ. (2012). Anxiolytic effects of 5-HT1A receptors and anxiogenic effects of 5-HT2C receptors in the amygdala of mice. Neuropharmacology62, 474–484. 10.1016/j.neuropharm.2011.09.002
117
LimaF. B.CentenoM. L.CostaM. E.ReddyA. P.CameronJ. L.BetheaC. L. (2009). Stress sensitive female macaques have decreased fifth Ewing variant (Fev) and serotonin-related gene expression that is not reversed by citalopram. Neuroscience164, 676–691. 10.1016/j.neuroscience.2009.08.010
118
LinthorstA. C. E.FlachskammC.HopkinsS. J.HoadleyM. E.LabeurM. S.HolsboerF.et al. (1997). Long-Term intracerebroventricular infusion of corticotropin-releasing hormone alters neuroendocrine, neurochemical, autonomic, behavioral, and cytokine responses to a systemic inflammatory challenge. J. Neurosci. 17, 4448–4460.
119
LinthorstA. C. E.PeñalvaR. G.FlachskammC.HolsboerF.ReulJ. M. H. M. (2002). Forced swim stress activates rat hippocampal serotonergic neurotransmission involving a corticotropin-releasing hormone receptor-dependent mechanism. Eur. J. Neurosci. 16, 2441–2452. 10.1046/j.1460-9568.2002.02400.x
120
Ljubic-ThibalV.MorinA.DiksicM.HamelE. (1999). Origin of the serotonergic innervation to the rat dorsolateral hypothalamus: retrograde transport of cholera toxin and upregulation of tryptophan hydroxylase mRNA expression following selective nerve terminals lesion. Synapse32, 177–186. 10.1002/(SICI)1098-2396(19990601)32:3<177::AID-SYN4>3.0.CO;2-D
121
LovejoyD. A.JahanS. (2006). Phylogeny of the corticotropin-releasing factor family of peptides in the metazoa. Gen. Comp. Endocrinol. 146, 1–8. 10.1016/j.ygcen.2005.11.019
122
LovenbergT. W.LiawC. W.GrigoriadisD. E.ClevengerW.ChalmersD. T.De SouzaE. B.et al. (1995). Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. U.S.A. 92, 836–840. 10.1073/pnas.92.3.836
123
LowryC. A. (2002). Functional subsets of serotonergic neurones: implications for control of the hypothalamic-pituitary-adrenal axis. J. Neuroendocrinol. 14, 911–923. 10.1046/j.1365-2826.2002.00861.x
124
LowryC. A.HaleM. W.EvansA. K.HeerkensJ.StaubD. R.GasserP. J.et al. (2008). Serotonergic systems, anxiety, and affective disorder. Ann. N.Y. Acad. Sci. 1148, 86–94. 10.1196/annals.1410.004
125
LowryC. A.HollisJ. H.de VriesA.PanB.BrunetL. R.HuntJ. R. F.et al. (2007). Identification of an immune-responsive mesolimbocortical serotonergic system: potential role in regulation of emotional behavior. Neuroscience146, 756–772. 10.1016/j.neuroscience.2007.01.067
126
LowryC. A.JohnsonP. L.Hay-SchmidtA.MikkelsenJ.ShekharA. (2005). Modulation of anxiety circuits by serotonergic systems. Stress8, 233–246. 10.1080/10253890500492787
127
LowryC. A.RoddaJ. E.LightmanS. L.IngramC. D. (2000). Corticotropin-releasing factor increases in vitro firing rates of serotonergic neurons in the rat dorsal raphe nucleus: evidence for activation of a topographically organized mesolimbocortical serotonergic system. J. Neurosci. 20, 7728–7736.
128
LukkesJ. L.ForsterG. L.RennerK. J.SummersC. H. (2008). Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphé differentially affect serotonin release in the nucleus accumbens. Eur. J. Pharmacol. 578, 185–193. 10.1016/j.ejphar.2007.09.024
129
LukkesJ. L.StaubD. R.DietrichA.TruittW.Neufeld-CohenA.ChenA.et al. (2011). Topographical distribution of corticotropin-releasing factor type 2 receptor-like immunoreactivity in the rat dorsal raphe nucleus: co-localization with tryptophan hydroxylase. Neuroscience183, 47–63. 10.1016/j.neuroscience.2011.03.047
130
MagierekV.RamosP. L.da Silveira-FilhoN. G.NogueiraR. L.Landeira-FernandezJ. (2003). Context fear conditioning inhibits panic-like behavior elicited by electrical stimulation of dorsal periaqueductal gray. Neuroreport14, 1641–1644. 10.1097/00001756-200308260-00020
131
MeloniE. G.ReedyC. L.CohenB. M.CarlezonW. A.Jr. (2008). Activation of raphe efferents to the medial prefrontal cortex by corticotropin-releasing factor: correlation with anxiety-like behavior. Biol. Psychiatry63, 832–839. 10.1016/j.biopsych.2007.10.016
132
MitchellA. J. (1998). The role of corticotropin releasing factor in depressive illness: a critical review. Neurosci. Biobehav. Rev. 22, 635–651. 10.1016/S0149-7634(97)00059-6
133
MullerM. B.ZimmermannS.SillaberI.HagemeyerT. P.DeussingJ. M.TimplP.et al. (2003). Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci. 6, 1100–1107. 10.1038/nn1123
134
Neufeld-CohenA.EvansA. K.GetselterD.SpyroglouA.HillA.GilS.et al. (2010a). Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol. Psychiatry15, 426–441. 10.1038/mp.2009.115
135
Neufeld-CohenA.TsooryM. M.EvansA. K.GetselterD.GilS.LowryC. A.et al. (2010b). A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proc. Natl. Acad. Sci. U.S.A. 107, 19020–19025. 10.1073/pnas.1013761107
136
Neufeld-CohenA.KellyP. A. T.PaulE. D.CarterR. N.SkinnerE.OlvermanH. J.et al. (2012). Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge. Biol. Psychiatry72, 437–447. 10.1016/j.biopsych.2012.05.005
137
O'HearnE.MolliverM. E. (1984). Organization of raphe-cortical projections in rat: a quantitative retrograde study. Brain Res. Bull. 13, 709–726. 10.1016/0361-9230(84)90232-6
138
ParkS. M.WilliamsC. L (2012). Contribution of serotonin type 3 receptors in the successful extinction of cued or contextual fear conditioned responses: interactions with GABAergic signaling. Rev. Neurosci. 23, 555–569. 10.1515/revneuro-2012-0052
139
PatelR.SprengR. N.ShinL. M.GirardT. A. (2012). Neurocircuitry models of posttraumatic stress disorder and beyond: a meta-analysis of functional neuroimaging studies. Neurosci. Biobehav. Rev. 36, 2130–2142. 10.1016/j.neubiorev.2012.06.003
140
PaulE. D.HaleM. W.LukkesJ. L.ValentineM. J.SarchetD. M.LowryC. A. (2011). Repeated social defeat increases reactive emotional coping behavior and alters functional responses in serotonergic neurons in the rat dorsal raphe nucleus. Physiol. Behav. 104, 272–282. 10.1016/j.physbeh.2011.01.006
141
PaxinosG.WatsonC. (1998). The Rat Brain in Stereotaxic Coordinates, 4th Edn. San Diego, CA: Academic.
142
PentkowskiN. S.DukeF. D.WeberS. M.PockrosL. A.TeerA. P.HamiltonE. C.et al. (2010). Stimulation of medial prefrontal cortex serotonin 2C (5-HT2C) receptors attenuates cocaine-seeking behavior. Neuropsychopharmacology35, 2037–2048. 10.1038/npp.2010.72
143
PernarL.CurtisA. L.ValeW. W.RivierJ. E.ValentinoR. J. (2004). Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions. J. Neurosci. 24, 1305–1311. 10.1523/JNEUROSCI.2885-03.2004
144
PerrinM. H.DonaldsonC. J.ChenR.LewisK. A.ValeW. W. (1993). Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology133, 3058–3061. 10.1210/en.133.6.3058
145
PerrinM. H.GraceC. R. R.RiekR.ValeW. W. (2006). The three-dimensional structure of the n-terminal domain of corticotropin-releasing factor receptors. Ann. N.Y. Acad. Sci. 1070, 105–119. 10.1196/annals.1317.065
146
PetitJ.-M.LuppiP.-H.PeyronC.RamponC.JouvetM. (1995). VIP-like immunoreactive projections from the dorsal raphe and caudal linear raphe nuclei to the bed nucleus of the stria terminalis demonstrated by a double immunohistochemical method in the rat. Neurosci. Lett. 193, 77–80. 10.1016/0304-3940(95)11669-N
147
PeyronC.PetitJ. M.RamponC.JouvetM.LuppiP. H. (1997). Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience82, 443–468. 10.1016/S0306-4522(97)00268-6
148
PhelpsE. A.LeDouxJ. E. (2005). Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron48, 175–187. 10.1016/j.neuron.2005.09.025
149
PorrinoL. J.Goldman-RakicP. S. (1982). Brainstem innervation of prefrontal and anterior cingulate cortex in the rhesus monkey revealed by retrograde transport of HRP. J. Comp. Neurol. 205, 63–76. 10.1002/cne.902050107
150
PotterE.SuttonS.DonaldsonC.ChenR.PerrinM.LewisK.et al. (1994). Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc. Natl. Acad. Sci. U.S.A. 91, 8777–8781. 10.1073/pnas.91.19.8777
151
PriceM. L.CurtisA. L.KirbyL. G.ValentinoR. J.LuckiI. (1998). Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology18, 492–502. 10.1016/S0893-133X(97)00197-8
152
PriceM. L.KirbyL. G.ValentinoR. J.LuckiI. (2002). Evidence for corticotropin-releasing factor regulation of serotonin in the lateral septum during acute swim stress: adaptation produced by repeated swimming. Psychopharmacology162, 406–414. 10.1007/s00213-002-1114-2
153
PriceM. L.LuckiI. (2001). Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor. J. Neurosci. 21, 2833–2841.
154
RainnieD. G. (1999). Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J. Neurophysiol. 82, 69–85.
155
ResslerK. J.NemeroffC. B. (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety12(Suppl. 1), 2–19. 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4
156
ReulJ. M. H. M.HolsboerF. (2002). Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2, 23–33. 10.1016/S1471-4892(01)00117-5
157
ReyesT. M.LewisK.PerrinM. H.KunitakeK. S.VaughanJ.AriasC. A.et al. (2001). Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98, 2843–2848. 10.1073/pnas.051626398
158
RobertsA. J.KruckerT.LevyC. L.SlaninaK. A.SutcliffeJ. G.HedlundP. B. (2004). Mice lacking 5-HT7 receptors show specific impairments in contextual learning. Eur. J. Neurosci. 19, 1913–1922. 10.1111/j.1460-9568.2004.03288.x
159
RocheM.CommonsK. G.PeoplesA.ValentinoR. J. (2003). Circuitry underlying regulation of the serotonergic system by swim stress. J. Neurosci. 23, 970–977.
160
RozeskeR. R.EvansA. K.FrankM. G.WatkinsL. R.LowryC. A.MaierS. F. (2011). Uncontrollable, but not controllable, stress desensitizes 5-ht1a receptors in the dorsal raphe nucleus. J. Neurosci. 31, 14107–14115. 10.1523/JNEUROSCI.3095-11.2011
161
RuggieroD. A.UnderwoodM. D.RiceP. M.MannJ. J.ArangoV. (1999). Corticotropic-releasing hormone and serotonin interact in the human brainstem: behavioral implications. Neuroscience91, 1343–1354. 10.1016/S0306-4522(98)00703-9
162
SakanakaM.ShibasakiT.LederisK. (1987). Corticotropin releasing factor-like immunoreactivity in the rat brain as revealed by a modified cobalt-glucose oxidase-diaminobenzidine method. J. Comp. Neurol. 260, 256–298. 10.1002/cne.902600209
163
SalamJ. N.FoxJ. H.DeTroyE. M.GuignonM. H.WohlD. F.FallsW. A. (2009). Voluntary exercise in C57 mice is anxiolytic across several measures of anxiety. Behav. Brain Res. 197, 31–40. 10.1016/j.bbr.2008.07.036
164
SaperC. B.LoewyA. D. (1980). Efferent connections of the parabrachial nucleus in the rat. Brain Res. 197, 291–317. 10.1016/0006-8993(80)91117-8
165
SchollJ. L.VuongS. M.ForsterG. L. (2010). Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala. Eur. J. Pharmacol. 644, 80–87. 10.1016/j.ejphar.2010.07.008
166
SenashovaO.ReddyA. P.CameronJ. L.BetheaC. L. (2012). The effect of citalopram on midbrain crf receptors 1 and 2 in a primate model of stress-induced amenorrhea. Reprod. Sci. 19, 623–632. 10.1177/1933719111430992
167
ShenH.SembaK. (1994). A direct retinal projection to the dorsal raphe nucleus in the rat. Brain Res. 635, 159–168. 10.1016/0006-8993(94)91435-4
168
ShenR.-Y.AndradeR. (1998). 5-Hydroxytryptamine2 receptor facilitates GABAergic neurotransmission in rat hippocampus. J. Pharmacol. Exp. Ther. 285, 805–812.
169
SinkK. S.WalkerD. L.FreemanS. M.FlandreauE. I.ResslerK. J.DavisM. (2013). Effects of continuously enhanced corticotropin releasing factor expression within the bed nucleus of the stria terminalis on conditioned and unconditioned anxiety. Mol. Psychiatry18, 308–319. 10.1038/mp.2011.188
170
SmithG. W.AubryJ.-M.DelluF.ContarinoA.BilezikjianL. M.GoldL. H.et al. (1998). Corticotropin releasing factor receptor 1–deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron20, 1093–1102. 10.1016/S0896-6273(00)80491-2
171
SmythiesJ. (2005). “Section V. Serotonin System,” in International Review of Neurobiology, Vol. 64, ed SmythiesJ. (Waltham, MA: Academic Press), 217–268.
172
StaubD. R.EvansA. K.LowryC. A. (2006). Evidence supporting a role for corticotropin-releasing factor type 2 (CRF2) receptors in the regulation of subpopulations of serotonergic neurons. Brain Res. 1070, 77–89. 10.1016/j.brainres.2005.10.096
173
StaubD. R.SpigaF.LowryC. A. (2005). Urocortin 2 increases c-Fos expression in topographically organized subpopulations of serotonergic neurons in the rat dorsal raphe nucleus. Brain Res. 1044, 176–189. 10.1016/j.brainres.2005.02.080
174
SteinbuschH. W. M. (1981). Distribution of serotonin-immunoreactivity in the central nervous system of the rat—Cell bodies and terminals. Neuroscience6, 557–618. 10.1016/0306-4522(81)90146-9
175
SteinbuschH. W. M.van der KooyD.VerhofstadA. A.PellegrinoA. (1980). Serotonergic and non-serotonergic projections from the nucleus raphe dorsalis to the caudate-putamen complex in the rat, studied by a combined immunofluorescence and fluorescent retrograde axonal labeling technique. Neurosci. Lett. 19, 137–142. 10.1016/0304-3940(80)90184-6
176
Stenzel-PooreM.HeinrichsS.RivestS.KoobG.ValeW. (1994). Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. 14, 2579–2584.
177
StezhkaV. V.LovickT. A. (1997). Projections from dorsal raphe nucleus to the periaqueductal grey matter: studies in slices of rat midbrain maintained in vitro. Neurosci. Lett. 230, 57–60. 10.1016/S0304-3940(97)00464-3
178
StiedlO.MisaneI.SpiessJ.ÖgrenS. O. (2000). Involvement of the 5-HT1A receptors in classical fear conditioning in C57BL/6J mice. J. Neurosci. 20, 8515–8527.
179
SwansonL. W.SawchenkoP. E.RivierJ.ValeW. W. (1983). Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology36, 165–186. 10.1159/000123454
180
TimplP.SpanagelR.SillaberI.KresseA.ReulJ. M. H. M.StallaG. K.et al. (1998). Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 19, 162–166. 10.1038/520
181
UnderwoodM. D.ArangoV.BakalianM. J.RuggieroD. A.MannJ. J. (1999). Dorsal raphe nucleus serotonergic neurons innervate the rostral ventrolateral medulla in rat. Brain Res. 824, 45–55. 10.1016/S0006-8993(99)01181-6
182
ValeW. W.RivierC.BrownM. R.SpiessJ.KoobG.SwansonL.et al. (1983). Chemical and biological characterization of corticotropin releasing factor. Recent Prog. Horm. Res. 39, 245–270.
183
ValeW. W.SpiessJ.RivierC.RivierJ. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science213, 1394–1397. 10.1126/science.6267699
184
ValentinoR. J.LioutermanL.Van BockstaeleE. J. (2001). Evidence for regional heterogeneity in corticotropin-releasing factor interactions in the dorsal raphe nucleus. J. Comp. Neurol. 435, 450–463. 10.1002/cne.1043
185
Van BockstaeleE. J.BiswasA.PickelV. M. (1993). Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens. Brain Res. 624, 188–198. 10.1016/0006-8993(93)90077-Z
186
van GaalenM. M.Stenzel-PooreM. P.HolsboerF.StecklerT. (2002). Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur. J. Neurosci. 15, 2007–2015. 10.1046/j.1460-9568.2002.02040.x
187
Van PettK.ViauV.BittencourtJ. C.ChanR. K. W.LiH.-Y.AriasC.et al. (2000). Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 428, 191–212. 10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U
188
VaughanJ.DonaldsonC.BittencourtJ.PerrinM. H.LewisK.SuttonS. W.et al. (1995). Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature378, 287–292. 10.1038/378287a0
189
VetterD. E.LiC.ZhaoL.ContarinoA.LibermanM. C.SmithG. W.et al. (2002). Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat. Genet. 31, 363–369. 10.1038/ng914
190
WangL.Goebel-StengelM.StengelA.WuS. V.OhningG.TachéY. (2011). Comparison of CRF-immunoreactive neurons distribution in mouse and rat brains and selective induction of Fos in rat hypothalamic CRF neurons by abdominal surgery. Brain Res. 1415, 34–46. 10.1016/j.brainres.2011.07.024
191
WangX.SuH.CopenhagenL. D.VaishnavS.PieriF.ShopeC. D.et al. (2002). Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. Mol. Cell. Biol. 22, 6605–6610. 10.1128/MCB.22.18.6605-6610.2002
192
WaselusM.NazzaroC.ValentinoR. J.Van BockstaeleE. J. (2009). Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. Biol. Psychiatry66, 76–83. 10.1016/j.biopsych.2009.02.014
193
WaterhouseB. D.BorderB.WahlL.MihailoffG. A. (1993). Topographic organization of rat locus coeruleus and dorsal raphe nuclei: distribution of cells projecting to visual system structures. J. Comp. Neurol. 336, 345–361. 10.1002/cne.903360304
194
WaterhouseB. D.MihailoffG. A.BaackJ. C.WoodwardD. J. (1986). Topographical distribution of dorsal and median raphe neurons projecting to motor, sensorimotor, and visual cortical areas in the rat. J. Comp. Neurol. 249, 460–476, 478-481. 10.1002/cne.902490403
195
WeissheimerK. V.HerodS. M.CameronJ. L.BetheaC. L. (2010). Interactions of corticotropin-releasing factor, urocortin and citalopram in a primate model of stress-induced amenorrhea. Neuroendocrinology92, 224–234. 10.1159/000319257
196
WeningerS. C.PetersL. L.MajzoubJ. A. (2000). Urocortin expression in the edinger-westphal nucleus is up-regulated by stress and corticotropin-releasing hormone deficiency. Endocrinology141, 256–263. 10.1210/en.141.1.256
197
ZayaraA.McIverG.ValdiviaP.LominacK.McCrearyA.SzumlinskiK. (2011). Blockade of nucleus accumbens 5-HT2A and 5-HT2C receptors prevents the expression of cocaine-induced behavioral and neurochemical sensitization in rats. Psychopharmacology213, 321–335. 10.1007/s00213-010-1996-3
198
ZhaoL.DonaldsonC. J.SmithG. W.ValeW. W. (1998). The structures of the mouse and human urocortin genes (Ucn and UCN). Genomics50, 23–33. 10.1006/geno.1998.5292
Summary
Keywords
anxiety, corticotropin-releasing factor, dorsal raphe nucleus, emotional behavior, serotonin
Citation
Fox JH and Lowry CA (2013) Corticotropin-releasing factor-related peptides, serotonergic systems, and emotional behavior. Front. Neurosci. 7:169. doi: 10.3389/fnins.2013.00169
Received
15 May 2013
Accepted
30 August 2013
Published
20 September 2013
Volume
7 - 2013
Edited by
David Lovejoy, University of Toronto, Canada
Reviewed by
Oline K. Ronnekleiv, Oregen Health and Science University, USA; Denise D. Belsham, University of Toronto, Canada
Copyright
© 2013 Fox and Lowry.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: James H. Fox, Behavioral Neuroendocrinology Laboratory, Department of Integrative Physiology and Center for Neuroscience, University of Colorado Boulder, 1725 Pleasant Street, Boulder, CO 80309-0354, USA e-mail: james.fox@colorado.edu
This article was submitted to Neuroendocrine Science, a section of the journal Frontiers in Neuroscience.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.